Disease · HP_0001649

Tachycardia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Tachycardia. Diseases, record HP_0001649. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001649

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Tachycardia
Open Targets ID: HP_0001649
Other names: Fast heart rate, Heart racing, Racing heart
Highest stage of its drugs: Phase 3, for 8 of its 19 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs19

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ESMOLOL	CHEMBL768	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
IVABRADINE	CHEMBL471737	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
METOPROLOL	CHEMBL13	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BEPOTASTINE BESYLATE	CHEMBL1201759	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BISOPROLOL	CHEMBL645	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CARVEDILOL	CHEMBL723	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PROPRANOLOL	CHEMBL27	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
LABETALOL	CHEMBL429	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 19

See all 19 drugs

Targets31

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRB1	Adrenergic receptor	9	Adrenergic receptor antagonist; Adrenergic receptor beta antagonist; Beta-1 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/153	Drugs and targets
ADRB2	Adrenergic receptor	5	Adrenergic receptor antagonist; Adrenergic receptor beta antagonist; Beta-2 adrenergic receptor antagonist	Phase 3	https://conductscience.org/library/genes/154	Drugs and targets
SCN10A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
SCN5A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6331	Drugs and targets
SCN7A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6332	Drugs and targets

1 to 10 of 31

See all 31 targets

Trials14

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02369900	Esmolol to Treat the Hemodynamic Effects of Septic Shock	Phase 2	40	2021-06-28	Septic Shock, Hypotension, Tachycardia	ESMOLOL	Its record names the disease	ClinicalTrials.gov
NCT01719367	Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation	Not applicable	38	2019-06-17	Atrial Fibrillation	ATENOLOL	Its record names the disease	ClinicalTrials.gov
NCT02997800	The Effect of Intraoperative Labetalol on Time to Discharge	Phase 2	172		Bloodpressure, Heart Rate	ESMOLOL, FENTANYL, LABETALOL	Open Targets' reading of its record	ClinicalTrials.gov
NCT02625454	Reduction of Intrapartum Fever With Intravenous Acetaminophen	Phase 2	168		Fever, Oxidative Stress	ACETAMINOPHEN	Its record names the disease	ClinicalTrials.gov
NCT07192081	Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy	Not applicable	116		Intubation, Anesthesia, Laparoscopic Cholecystectomy, Hemodynamic Response to Laryngoscopy	LABETALOL	Its record names the disease	ClinicalTrials.gov
NCT00700466	Intravenous Beta-blockade for Improvement of Autonomic Activity		100		Hypertension, Tachycardia, Heart Rate Variability	METOPROLOL	Its record names the disease	ClinicalTrials.gov
NCT05389176	Effects of Heart Control at Different Stages in Patients of Septic Shock With Tachycardia	Not applicable	96		Septic Shock, Tachycardia	ESMOLOL	Its record names the disease	ClinicalTrials.gov
NCT02462941	Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart	Phase 1	80		Sinus Bradycardia, Atrioventricular Block	ADENOSINE	Its record names the disease	ClinicalTrials.gov
NCT05292209	RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring	Phase 2	78		Atrial Fibrillation Paroxysmal	RILUZOLE	Its record names the disease	ClinicalTrials.gov
NCT01839253	The Effect of Antihypertensive Agents Concerning With Hemodynamics and Reduction of Anaesthetics in Orthognathic Surgery	Not applicable	75		Orthognathic Surgery	ATENOLOL, ENALAPRIL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 14

See all 14 trials

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Esmolol Infusion vs Standard Care, Saline: deaths from any cause	6 of 18	8 of 22	40	NCT02369900	Trial comparisons
Esmolol Infusion vs Standard Care, Saline: serious adverse events	4 of 18	0 of 22	40	NCT02369900	Trial comparisons
Atenolol: Ancestral Alleles vs Atenolol: Variant Carriers: deaths from any cause	0 of 19	0 of 19	38	NCT01719367	Trial comparisons
Atenolol: Ancestral Alleles vs Atenolol: Variant Carriers: serious adverse events	0 of 19	0 of 19	38	NCT01719367	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
16914460	RESULT	1	PubMed
12651674	RESULT	1	PubMed
42567080	DERIVED	1	PubMed
35066509	DERIVED	1	PubMed
33451627	DERIVED	1	PubMed
28450351	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001649

GET https://conductscience.org/api/diseases/v1/HP_0001649/targets?page=2

API reference For AI assistants